[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344215-105":59,"doc-detail-344215-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","real-world-study-of-egfr-tki-rechallenge-with-another-tki-after-first-line-osimertinib-discontinuation-a-subset-analysis-of-the-reiwa-study","Real-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer - A Subset Analysis of the Reiwa Study","","Real-world outcomes for EGFR-mutated non-small cell lung cancer after discontinuation of first-line osimertinib were assessed through a multicenter prospective observational subset analysis. The study evaluated efficacy and safety of EGFR-TKI rechallenge using a different EGFR-tyrosine kinase inhibitor as second- or third-line therapy. Fifty-three patients received rechallenge, with primary discontinuation drivers of toxicity and progressive disease. Results reported treatment failure timing, common rechallenge agents, and discontinuation due to toxicity without pneumonitis, concluding that rechallenge was generally well tolerated.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-study-of-egfr-tki-rechallenge-with-another-tki-after-first-line-osimertinib-discontinuation-a-subset-analysis-of-the-reiwa-study/344215/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-study-of-egfr-tki-rechallenge-with-another-tki-after-first-line-osimertinib-discontinuation-a-subset-analysis-of-the-reiwa-study/344215.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical problem does the study address?","Question",{"text":112,"@type":113},"The study examines efficacy and safety of EGFR-TKI rechallenge with a different TKI after stopping first-line osimertinib due to resistance or toxicity in EGFR-mutated NSCLC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Who were the participants and when was treatment given?",{"text":117,"@type":113},"Patients with EGFR-mutated NSCLC who received first-line osimertinib and another EGFR-TKI as second- or third-line therapy between September 2018 and August 2020 were enrolled.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the most common rechallenge EGFR-TKIs and key outcomes?",{"text":121,"@type":113},"Afatinib was most common, followed by gefitinib and erlotinib. The real-world time to treatment failure was 7.3 months, with longer duration in toxicity-related discontinuation than in progressive disease.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344215,1790192995,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Thoracic Cancer  \nORIGINAL ARTICLE  OPEN ACCESS   \nReal-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer:  \nA Subset Analysis of the Reiwa Study  \nKei Sonehara1  | Kazunari Tateishi1  | Kiyotaka Yoh2 | Kazuhiro Usui3 | Yukio Hosomi4 | Kazuma Kishi5 | Go Naka6,7 | Kageaki Watanabe4 | Shu Tamano8 | Kohei Uemura9 | Hideo Kunitoh10  \n1First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan | 2Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan | 3Respiratory Medicine, NTT Medical Center Tokyo, Shinagawa, Tokyo, Japan | 4Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan | 5Department of Respiratory Medicine, Toho University Omori Medical Center, Ota, Tokyo, Japan | 6Department of Respiratory Medicine, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan | 7Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Chiyoda, Tokyo, Japan | 8Biostatistics and Bioinformatics Course, Graduate School of Interdisciplinary Information Studies, The University of Tokyo, Bunkyo, Tokyo, Japan | 9Department of Biostatistics and Bioinformatics, the Interfaculty Initiative in Information Studies, The University of Tokyo,  \nBunkyo, Tokyo, Japan | 10Department of Chemotherapy, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan Correspondence: Kei Sonehara ([soneponpon@shinshu-u.ac.jp](soneponpon@shinshu-u.ac.jp))  \nReceived: 25 September 2024 | Revised: 7 November 2024 | Accepted: 25 November 2024  \nFunding: This work was supported by AstraZeneca.  \nKeywords: epidermal growth factor receptor | non-small cell lung cancer | osimertinib | rechallenge | tyrosine kinase inhibitor  \nABSTRACT  \nIntroduction: First-line osimertinib is widely used to treat patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancers (NSCLC) . In clinical practice, rechallenge therapy with another EGFR-tyrosine kinase inhibitor (TKI) is often performed after first-line TKI discontinuation owing to resistance or toxicity; however, the efficacy and toxicity of EGFR-TKI rechallenge after first-line osimertinib have not been adequately investigated. This study aimed to examine the efficacy and safety of EGFR-TKI rechallenge with another TKI.  \nMethods: This multicenter prospective observational study enrolled patients with EGFR-mutated NSCLC who received firstline osimertinib and another EGFR-TKI as second-or third-line treatment between September 2018 and August 2020.  \nResults: Fifty-three patients received rechallenge with another EGFR-TKI in the second-line (n = 38, 71.7%) or third-line (n = 15, 28.3%) setting. The primary reason for first-line osimertinib discontinuation was toxicity in 32 (60.4%, 17 patients with pneumonitis) and disease progression in 20 (37.7%) patients. The most common rechallenge EGFR-TKI was afatinib (n = 24, 45.3%), followed by gefitinib (n = 16, 30.2%) and erlotinib (n = 8, 15.1%). The real-world time to treatment failure (rwTTF) was 7.3 months. The rwTTF for the toxicity discontinuation and progressive disease discontinuation groups was 9.3 months and 5.1 months, respectively,(HR 1.61, p = 0.119) . EGFR-TKI rechallenge was discontinued due to toxicity in nine patients (17.0%), but no patient developed pneumonitis.  \nConclusion: EGFR-TKI rechallenge with another TKI is well tolerated in patients with EGFR-mutated NSCLC. Thus, it may bea useful treatment option after first-line osimertinib failure, especially after osimertinib discontinuation due to toxicity.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and i","cbCaikBuKQ3WCe65","https://ap.wps.com/l/cbCaikBuKQ3WCe65","pdf",332592,"English","# Introduction\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What clinical problem does the study address?\",\"answer\":\"The study examines efficacy and safety of EGFR-TKI rechallenge with a different TKI after stopping first-line osimertinib due to resistance or toxicity in EGFR-mutated NSCLC.\"},{\"question\":\"Who were the participants and when was treatment given?\",\"answer\":\"Patients with EGFR-mutated NSCLC who received first-line osimertinib and another EGFR-TKI as second- or third-line therapy between September 2018 and August 2020 were enrolled.\"},{\"question\":\"What were the most common rechallenge EGFR-TKIs and key outcomes?\",\"answer\":\"Afatinib was most common, followed by gefitinib and erlotinib. The real-world time to treatment failure was 7.3 months, with longer duration in toxicity-related discontinuation than in progressive disease.\"}]","Real-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer - A Subset Analysis of the Reiwa Study | PDF",1790053229,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0aaceb7f15bf725eab82c83c3b3b8e5e.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eca639db266584b523ae6f15edc69b17.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7751b9e3e16a26ad3e649dae1188b3fc.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a58a7e81614b79c0d4335d0db9dd803.webp",980,1287]